Table 1 Baseline patient characteristics (full analysis set)

From: Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study

 

Total

N = 93

ARB subcohort

n = 45

CCB subcohort

n = 48

Sex, male

47 (50.5)

22 (48.9)

25 (52.1)

Age, years

67.6 ± 11.6

66.5 ± 12.4

68.7 ± 10.7

Weight, kg

66.0 ± 15.6

67.7 ± 18.0

64.4 ± 13.1

Body mass index, kg/m2

25.5 ± 4.3

25.7 ± 4.7

25.4 ± 4.0

Nighttime home (brachial) SBP/DBP, mmHg

132.4 ± 10.4/78.4 ± 7.4

133.7 ± 12.1/79.9 ± 7.4

131.1 ± 8.4/76.9 ± 7.1

Nighttime home (wrist) SBP/DBP, mmHg

130.4 ± 14.5/73.1 ± 9.6

131.3 ± 15.7/73.9 ± 9.7

129.6 ± 13.4/72.3 ± 9.5

Morning home SBP/DBP, mmHg

143.8 ± 13.3/86.7 ± 9.8

144.8 ± 14.9/88.8 ± 10.8

142.9 ± 11.8/84.6 ± 8.2

Bedtime home SBP/DBP, mmHg

135.1 ± 13.6/80.5 ± 9.8

135.9 ± 15.2/82.3 ± 10.7

134.4 ± 12.1/78.8 ± 8.7

Office SBP/DBP, mmHg

147.2 ± 17.8/84.1 ± 12.3

145.9 ± 20.1/84.8 ± 12.8

148.5 ± 15.5/83.4 ± 11.8

Duration of hypertension, months

140.2 ± 122.1

157.4 ± 133.9

125.4 ± 110.3

PAC, pg/ml

39.4 ± 36.8

28.5 ± 23.2

49.7 ± 43.8

PRA, ng/ml/h

2.7 ± 5.8

4.2 ± 8.0

1.3 ± 1.4

Serum potassium, mEq/l

4.0 ± 0.4

4.2 ± 0.4

3.9 ± 0.4

eGFRcreat, ml/min/1.73 m2

69.7 ± 17.1

66.1 ± 15.9

73.1 ± 17.6

 <30

0

0

0

 30–<60

30 (32.3)

19 (42.2)

11 (22.9)

 ≥60

63 (67.7)

26 (57.8)

37 (77.1)

UACR, mg/gCr

110.4 ± 321.5

121.4 ± 302.5

100.1 ± 341.1

 <30

65 (69.9)

29 (64.4)

36 (75.0)

 30–<300

19 (20.4)

11 (24.4)

8 (16.7)

 ≥300

9 (9.7)

5 (11.1)

4 (8.3)

NT-proBNP, pg/ml

83.7 ± 92.3

79.6 ± 75.3

87.4 ± 106.5

Other complications

 Type 2 DM

33 (35.5)

23 (51.1)

10 (20.8)

 Diabetic retinopathya

8 (8.6)

7 (15.6)

1 (2.1)

 Dyslipidemia

52 (55.9)

27 (60.0)

25 (52.1)

 Hyperuricemia

17 (18.3)

9 (20.0)

8 (16.7)

 Heart failure

1 (1.1)

0

1 (2.1)

Smoking

14 (15.1)

7 (15.6)

7 (14.6)

Dose of esaxerenone at the end of treatment (last dose)

 1.25 mg

14 (15.1)

13 (28.9)

1 (2.1)

 2.5 mg

45 (48.4)

17 (37.8)

28 (58.3)

 5 mg

34 (36.6)

15 (33.3)

19 (39.6)

  1. Data are n (%) or mean ± SD
  2. ARB angiotensin receptor blocker, CCB calcium-channel blocker, DBP diastolic blood pressure, DM diabetes mellitus, eGFRcreat creatinine-based estimate of the glomerular filtration rate, NT-proBNP N-terminal pro-brain natriuretic peptide, PAC plasma aldosterone concentration, PRA plasma renin activity, SBP systolic blood pressure, UACR urinary albumin-to-creatinine ratio
  3. aBased on the Davis classification; included patients diagnosed with simple retinopathy, pre-proliferative retinopathy, or proliferative retinopathy
Back to article page